Bicalutamide Monotherapy Versus Leuprolide Monotherapy for Prostate Cancer: Effects on Bone Mineral Density and Body Composition

Smith, Matthew R., Goode, Melissa, Zietman, Anthony L., McGovern, Francis J., Lee, Hang, Finkelstein, Joel S.·2004·Journal of Clinical Oncology
DOI 10.1200/jco.2004.01.174

Cited by (188)

Items 101–188 of 188

  1. Adverse metabolic consequences of androgen deprivation therapy (ADT) on Asian patients with prostate cancer: Primary results from the real‐life experience of ADT in Asia (READT) study
    Chris Ho Ming Wong, Ning Xu, Jasmine Lim, Kuo-Kang Feng, Wayne KW Chan, Marco T. Y. Chan, Steven C. H. Leung, Dong‐Ning Chen, Yun‐Zhi Lin, Peter Ka‐Fung Chiu et al. · 2023 · The Prostate
  2. Cardiovascular Disease Associated With Androgen-Deprivation Therapy: Time to Give It Due Respect
    Shehzad Sultan Basaria · 2015 · Journal of Clinical Oncology
  3. Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide
    Giulia Baciarello, Cora Nanette Sternberg · 2016 · Critical Reviews in Oncology/Hematology
  4. GnRH agonists and antagonists in prostate cancer
    Robert Janknegt, Niels W. Boone, Frans Erdkamp, Victor Zambon · 2014 · Generics and Biosimilars Initiative Journal
  5. A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer
    Thai H. Ho, Rafael Núñez-Nateras, Yue-Xian Hou, Alan Haruo Bryce, DW Northfelt, Amylou Constance Dueck, Bryan Y. Wong, Melissa Stanton, Richard Wayne Joseph, Erik P. Castle · 2016 · Clinical Genitourinary Cancer
  6. Emerging drugs for the management of cancer treatment induced bone loss
    Francesco Bertoldo, Serena Pancheri, Sonia Zenari, Stefania Boldini · 2010 · Expert Opinion on Emerging Drugs
  7. Effects of short-term sex steroid suppression on dietary fat storage patterns in healthy males
    Rynders, Corey A., Schmidt, Stacy L., Bergouignan, Audrey, Horton, Tracy J., Bessesen, Daniel H. · 2018 · Physiological Reports
  8. AST-induced bone loss in men with prostate cancer: exercise as a potential countermeasure
    Kate A. Bolam, Daniel Abido Galvao, Nigel A. Spry, Robert Usher Newton, Dennis R. Taaffe · 2012 · Prostate Cancer and Prostatic Diseases
  9. Surgery and hormonal treatment for prostate cancer and sexual function.
    Katie Lynn Canalichio, Yasmeen Jaber, Run Wang · 2015 · PubMed Central
  10. Loss of bone mass in patients with prostate cancer subjected to androgenic deprivation
    Juan Moróte, Jacques Planas · 2011 · Actas Urológicas Españolas (English Edition)
  11. How can we improve the physical stability of co-amorphous system containing flutamide and bicalutamide? The case of ternary amorphous solid dispersions.
    Justyna Pacułt, Marzena Rams‐Baron, Krzysztof Chmiel, Karolina Jurkiewicz, Agata Antosik, Joanna Szafraniec-Szczęsny, Mateusz Kurek, Renata Jachowicz, Marian Paluch · 2021 · European Journal of Pharmaceutical Sciences
  12. Inhibitors of the Transactivation Domain of Androgen Receptor as a Therapy for Prostate Cancer
    Jon K. Obst, Amy H. Tien, Josie Setiawan, Lauren F. Deneault, Marianne D. Sadar · 2024 · Steroids
  13. Network meta-analysis of the efficacy and adverse effects of several treatments for advanced/metastatic prostate cancer
    Jing Wu, Weikang Chen, Wei Zhang, Jinsong Zhang, Jianhe Liu, Yongming Jiang, Ke-Wei Fang · 2017 · Oncotarget
  14. Comparative Effects of Bicalutamide (Casodex) versus Orchidectomy on Bone Mineral Density, Bone Remodelling, and Bone Biomechanics in Healthy Rats
    Mar Lefort, Díaz Curiel M, Maria Teresa Carrascal, Cioly Méndez‐Dávila, Concepción de la Piedra · 2005 · Urologia Internationalis
  15. Hormonal Therapy in the Elderly Prostate Cancer Patient
    Jesco Pfitzenmaier, Jens Erik Altwein · 2009 · Deutsches Ärzteblatt international
  16. Systemic Therapy for the Treatment of Hormone-Sensitive Metastatic Prostate Cancer: from Intermittent Androgen Deprivation Therapy to Chemotherapy
    Bobby Chi-Hung Liaw, Jeffrey W. Shevach, William K. Oh · 2015 · Current Urology Reports
  17. Sexual Function in Men Undergoing Androgen Deprivation Therapy
    Gustavo M. Gryzinski, Judy N. Fustok, Omer A. Raheem, Helen Levey Bernie · 2022 · Androgens Clinical Research and Therapeutics
  18. Anti-androgen monotherapy for metastatic prostate cancer
    Gerhardt Attard · 2014 · The Lancet Oncology
  19. Review: Risk stratification in the hormonal treatment of patients with prostate cancer
    Matthew A. Uhlman, Judd W. Moul, Ping Tang, Danielle A. Stackhouse, Leon L Sun · 2009 · Therapeutic Advances in Medical Oncology
  20. Preferences of hxealthy men for two different endocrine treatment options offered for locally advanced prostate cancer
    Valerie A. Jenkins, Lesley J. Fallowfield, Trudi L. Edginton, Heather Ann Payne, E. Hamilton · 2005 · Current Medical Research and Opinion
  21. 4-OH tamoxifen does not interfere with bicalutamide inhibitory effects on human prostatic cancer cells in vitro.
    Francesco Boccardo, D Medicina, Fabia Galmozzi, Laura Emionite, Martina Lo Casto · 2005 · PubMed
  22. Evolution of hormonal therapy for prostate cancer
    David Homewood, Ming Hei Fu, Niranjan Jude Sathianathen, Shane La Bianca, Benjamin Tran, Niall M. Corcoran · 2024 · Australian Journal of General Practice
  23. Skeletal complications of ADT: disease burden and treatment options
    Jacques Planas, Juan Moróte · 2012 · Asian Journal of Andrology
  24. Testosterone: More Is Not Always Better
    Sundeep Khosla · 2009 · The Journal of Clinical Endocrinology & Metabolism
  25. Approaches to minimize castration in the treatment of advanced prostate cancer
    Kreshnik Zejnullahu, María Garrido Arévalo, Charles J. Ryan, Rahul Raj Aggarwal · 2016 · Urologic Oncology Seminars and Original Investigations
  26. The benefits of early androgen blockade
    PAUL D. MARONI, E. David Crawford · 2008 · Best Practice & Research Clinical Endocrinology & Metabolism
  27. Clodronate in the prevention and treatment of skeletal metastasis
    James L. Gulley, William L. Dahut · 2005 · Expert Review of Anticancer Therapy
  28. Zoledronic acid prevents decreases in bone mineral density in patients with prostate cancer undergoing combined androgen blockade
    Satoshi Nishizawa, Takeshi Inagaki, Akinori Iba, Kazuro Kikkawa, Yoshiki Kodama, Nagahide Matsumura, Yasuo Kohjimoto, Isao Hara · 2014 · SpringerPlus
  29. Androgen Deprivation Therapy in Prostate Cancer - Current Status in M1 Patients
    Hocine Habchi, Nicolas Mottet · 2015 · Oncology Research and Treatment
  30. Osteoporosis Associated with Cancer Therapy
    Ailleen Heras-Herzig, Wende Kozlow, Sue A. Brown, Theresa A. Guise · 2008 · Elsevier eBooks
  31. Sexuality and intimacy after cancer
    Jennifer E. Potter, Katherine T. Johnston · 2011 · Elsevier eBooks
  32. In Reply:
    Francesco Boccardo, ALESSANDRA RUBAGOTTI · 2005 · Journal of Clinical Oncology
  33. Cancer Treatment-Induced Bone Loss (CTIBL)
    Catarina Abreu, Maria Rita Dionísio, Joana Caldeira Fernandes da Silva, Luís Costa · 2018 · Elsevier eBooks
  34. Effect of bicalutamide on serum total testosterone concentration in transgender adults: a case series
    Lachlan M. Angus, Quoc Vinh Hong, Ada S. Cheung, Brendan J. Nolan · 2024 · Therapeutic Advances in Endocrinology and Metabolism
  35. Körperliche Bewegung in der onkologischen Palliativmedizin
    Elke Jäger · 2012 · Springer eBooks
  36. Hormonal therapy in metastatic prostate cancer: current perspectives and controversies
    Manish Garg, Vishwajeet Singh, Manoj Kumar, Satyanarayan Sankhwar · 2013 · Oncology Reviews
  37. Management of fatigue and anaemia in men treated with androgen deprivation therapy
    Alejo Rodríguez‐Vida, Subhra Chowdhury, Simon Chowdhury · 2014 · Trends in Urology & Men s Health
  38. Androgen Receptor Antagonists
    Howard C. Shen, Mary‐Ellen Taplin, Steven P. Balk · 2010 · Springer eBooks
  39. Drugging the intrinsically disordered transactivation domain of androgen receptor
    Jon K. Obst, Carmen Adriana Banuelos, Kunzhong Jian, Amy H. Tien, Oleksandr A. Shkrabak, Jun Wang, Nasrin R. Mawji, Teresa Tam, Marija Vuckovic, David E. Williams et al. · 2026 · Signal Transduction and Targeted Therapy
  40. Bone metastases in prostate cancer: pathophysiology, clinical complications, actual treatment, and future directions
    Fernanda Gabriela Herrera, Thomas Tawadros, Dominik Berthold · 2014 · Elsevier eBooks
  41. Bone health in patients with prostate cancer
    B. Miñana, Jose M. Cozar, Antonio Alcaraz, Juan Moróte, Francisco Gómez-Veiga, E. Solsona, Alfredo Rodríguez-Antolín, Joaquı́n Carballido · 2014 · Actas Urológicas Españolas (English Edition)
  42. Osteoporosis tras la curación tumoral
    José Manuel Olmos, J. González Macías · 2007 · Medicina Clínica
  43. Male Osteoporosis
    Stephen Paul Tuck, R. M. Francis, Birgit C. Hanusch · 2013 · Osteologie/Osteology
  44. Perte osseuse liée aux hormonomodulateurs
    Karine Briot, Christian Roux · 2009 · ONCOLOGIE
  45. Stepping-stones to the further advancement of androgen-deprivation therapy for prostate cancer
    Tsutomu Nishiyama, Kazuya Z. Suzuki, Kazutoshi Yamana, 悦子 利根川, Koichi Wako, Kota Takahashi · 2006 · Expert Review of Anticancer Therapy
  46. Bone health and its correlates in Korean prostate cancer patients receiving androgen deprivation therapy
    Soo Hyun Kim, Do Hwan Seong, Sang Min Yoon, Young Deuk Choi, Youngkyu Song, Hosook Song, Eunju Choi · 2015 · European Journal of Oncology Nursing
  47. Prévention osseuse dans le traitement du cancer de la prostate
    Th. Bessede · 2011 · The French Journal of Urology
  48. ADT and acute kidney injury—causal or casual relationship?
    Matthew Raymond Smith · 2013 · Nature Reviews Endocrinology
  49. Manifestations ostéoarticulaires des hormonomodulateurs
    Karine Briot, Christian Roux · 2008 · Revue du Rhumatisme
  50. Physical Exercise in Advanced Malignant Diseases
    Winfried E. Banzer, Eszter Füzéki, Marcus Bernhörster, Elke Jäger · 2012 · Springer eBooks
  51. Androgen Deprivation Therapy for Advanced Prostate Cancer
    Peter Hammerer, Lukas Manka · 2019 · Springer eBooks
  52. Evaluation of Trabecular Microstructure of Cancellous Bone Using Quarter-Detector Computed Tomography
    Hiroaki HASEGAWA, Nobuhito Nango, Masafumi Machida · 2023 · Diagnostics
  53. Metabolic Health for Patients with Prostate Cancer During Androgen Deprivation Therapy
    Koji Mitsuzuka, Yoichi Arai · 2018 · Springer eBooks
  54. Pérdida de masa ósea en pacientes con cáncer de próstata sometidos a deprivación androgénica
    Juan Moróte, Jacques Planas · 2011 · Actas Urológicas Españolas
  55. Osteoporosis, Androgen Levels and Urological Care
    Robert A. Adler · 2010 · The Journal of Urology
  56. Meeting report from skeletal complications of malignancy IV
    Robert L. Vessella, Theresa A. Guise, Edward S Susman, Larry J. Suva, Gregory A. Clines, Scott L. Kominsky, KRISTY L. WEBER, John M. Chirgwin, Laurie K. McCauley, Wende Kozlow · 2006 · BoneKEy-Osteovision
  57. A Psycho-Education Intervention to Help Men with Prostate Cancer Adapt to Androgen Deprivation Therapy
    Lauren M. Walker · 2013 · Libraries and Cultural Resources (University of Calgary)
  58. The role of highly selective androgen receptor (AR) targeted therapy in men with biochemically relapsed hormone sensitive prostate cancer.
    Rahul Raj Aggarwal, Joshi J. Alumkal, Russell Zelig Szmulewitz, Celestia S. Higano, Alan Haruo Bryce, Margaret K. Yu, Carla de Boer, Gonzalo Choque-Gonzales, Eric Jay Small · 2015 · Journal of Clinical Oncology
  59. Treatment Modalities in Prostate Cancer
    İsmaıl Evren, Volkan Tuğcu · 2018 · Nuclear Medicine Seminars
  60. Hormonal treatment for progression
    Kurt Miller · 2009 · European Journal of Cancer
  61. Hormonal and Chemotherapeutic Options in Advanced Prostate Cancer
    Kevin S. Art, Jeffrey M. Holzbeierlein · 2008 · Aging Health
  62. Challenges in overcoming hormonal resistance in prostate cancer
    Avani Atul Shah, William D. Figg, William L. Dahut · 2014 · Clinical Investigation
  63. Managing locally advanced prostate cancer: a urologist??s and a patient??s perspective
    Roger Sinclair Kirby, Nigel Offen · 2006 · Anti-Cancer Drugs
  64. Salud ósea en pacientes con cáncer de próstata
    Bernardino Miñana López, Jose M. Cozar, Antonio Alcaraz, Juan Moróte, Francisco Gómez-Veiga, E. Solsona, Alfredo Rodríguez-Antolín, Joaquı́n Carballido · 2014 · Actas Urológicas Españolas
  65. Determinants of Physical Aging among Healthy Postmenopausal Women and their Relation with Serum Hormone Levels
    Corinne E. I. Lebrun · 2008 · EUR Research Repository (Erasmus University Rotterdam)
  66. Overexpression of Androgen Receptor in Prostate Cancer
    Alfonso Urbanucci · 2012 · Tampere University Institutional Repository (Tampere University)
  67. Pathophysiology—Prostate Cancer
    Philip James Saylor, Matthew Raymond Smith · 2013 · Elsevier eBooks
  68. Hormonal Therapy in Metastatic Prostate Cancer
    Yakup Kordan · 2010 · Türk Üroloji Seminerleri/Turkish Urology Seminars
  69. Prévention osseuse dans le traitement du cancer de la prostate
    Journées d'Onco-Urologie Médicale · 2011
  70. Hormonal Therapies for Patients with Advanced Prostate Cancer
    Cora Nanette Sternberg, Bertrand F. TOMBAL · 2016 · European Medical Journal
  71. Bone Metastases of Prostatic Cancer
    Sara De Dosso, Fernanda Gabriela Herrera, Dominik Berthold · 2010 · Elsevier eBooks
  72. The Role of Hormonal Treatment in Prostate Cancer
    Pervin Hürmüz, Fadil H. Akyol, Melis Gültekin, Gözde Yazıcı, Sezin Yüce Sarı, Gökhan Özyiğit · 2017 · Springer eBooks
  73. Effect of maximal androgen blockade therapy on hematological, biochemical and bone density in locally advanced prostate cancer
    Erhan Demirelli, Ahmet Hakan Haliloğlu, Ömer Gülpınar, Mehmet Giray Sönmez, Yaşar Bedük, Sadettin Küpeli · 2018 · Acta Medica Alanya
  74. Androgen Deprivation Therapy for Advanced Prostate Cancer
    Peter Hammerer, Lukas Manka · 2018 · Springer eBooks
  75. Phase II open-label study investigating apalutamide in patients with biochemical progression after radical prostatectomy
    Piet R. Dirix, Michiel Hendrik Strijbos, Tom Van den Mooter, Nick Liefhooghe, Siska Van Bruwaene, Pieter Uvin, Christophe Ghysel, Dieter Ost, Peter Schatteman, Samuel Bral et al. · 2020 · Future Oncology
  76. Drug-Induced Male Osteoporosis
    Valentina Camozzi · 2020 · Trends in andrology and sexual medicine
  77. Active treatment of prostate cancer
    Greetta Hackman · 2021 · Työväentutkimus Vuosikirja
  78. Neoplasms of the Prostate
    Christopher J. Logothetis, Jeri Kim, John Warren Davis, Brian Francis Chapin, Deborah Ann Kuban, Eleni Efstathiou, Ana M. Aparicio · 2017 · Holland‐Frei Cancer Medicine
  79. Prostate Cancer
    Rahul Raj Aggarwal, Eric Jay Small · 2014 · Springer eBooks
  80. Testosterone
    Jeffrey D. Zajac, Ego Seeman, Nicholas Russell, Sabashini K. Ramchand, Ingrid Bretherton, Mathis Grossmann, Rachel A. Davey · 2020 · Elsevier eBooks
  81. Neoplasms of the Prostate
    Ana M. Aparicio, Patrick Glen Pilie, Devaki Shilpa Surasi, Seungtaek Choi, Brian Francis Chapin, Christopher J. Logothetis, Paul Gettys Corn · 2022 · Holland‐Frei Cancer Medicine
  82. Talking about sex: erectile dysfunction in the oncology patient
    Marilina Romeo, Giorgia Spaggiari, Chiara Furini, Antonio R. M. Granata, Angela Toss, Manuela Simoni, Daniele Santi · 2023 · Endocrine Related Cancer
  83. Lhrh Agonist and Antagonist for Metastatic Prostate Cancer
    Bekir Demirtaş, Hüseyin Özgür Kazan · 2024
  84. ADT Combinations With Radiation for Prostate Cancer: A Systematic Review and Meta-analysis
    Jamie Takayesu, Tian Xie, Jessica Aldous, Batoul Nasser, Joshi J. Alumkal, Robert Timothy Dess, Zachery Roger Reichert, Matthew J. Schipper, Daniel Eidelberg Spratt, Krithika Suresh et al. · 2026 · International Journal of Radiation Oncology*Biology*Physics
  85. Wechselwirkungen zwischen onkologischer Medikation und körperlicher Aktivität
    Elke Jäger · 2012 · Springer eBooks
  86. Prostate Cancer
    Ivan de Kouchkovsky, Eric Small, Rahul R. Aggarwal · 2026 · Springer eBooks
  87. Cancer Treatment-Induced Bone Loss (CTIBL)
    Catarina M. Abreu, Maria Rita Dionísio, J. A. Pereira Silva, Luis Costa · 2019 · Elsevier eBooks
  88. Role of bone microarchitecture and hereditary determinants of bone fragility
    Hoda Abdelmohsen Ali Mohamed Nagy · 2013